Methods and compositions for liposomal formulation of antigens and uses thereof

Patent metadata

Field	Value
Publication number	US-10369229-B2
Application number	US-201815943382-A
Country	US
Kind code	B2
Filing date	Apr 2, 2018
Priority date	Mar 9, 2009
Publication date	Aug 6, 2019
Grant date	Aug 6, 2019

Abstract

The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).

First claim

The invention claimed is:

1. A composition comprising:
an aqueous vehicle; and
liposomes comprising
(i) dimyristoylphosphatidylcholine (“DMPC”),
(ii) dimyristoylphosphatidylglycerol (“DMPG”), dimyristoyltrimethylammonium propane (“DMTAP”), or both DMPG and DMTAP, and
(iii) at least one reactive sterol derivative, wherein between 1% and 100% of said at least one sterol derivatives comprise an influenza M2 antigen polypeptide sequence covalently linked thereto.

2. A composition according to claim 1 , wherein said relative percentages are 70%-85% (i): 5%-15% (ii): 10%-15% (iii).

3. A composition according to claim 1 , wherein said relative percentages are about 75% (i), about 10% (ii), and about 15% (iii).

4. A composition according to claim 1 , wherein said liposomes are substantially between 50 and 500 nm in diameter.

5. A composition according to claim 4 , wherein said liposomes are substantially between 50 and 200 nm in diameter.

6. A composition according to claim 4 , wherein said liposomes are substantially between 50 and 150 nm in diameter.

7. A composition according to any of claim 1 , wherein the lipid in (ii) is DMPG.

8. A composition according to claim 1 , wherein said sterol derivative(s) is/are derivative(s) of cholesterol, cholesteryl chloroformate, stigmasterol, sitosterol, ergosterol, lanosterol, desmosterol, or campesterol.

9. A composition according to claim 1 , wherein the functional moiety is a maleimide.

10. A composition according to claim 1 , further comprising an adjuvant.

11. A composition according to claim 10 , wherein the adjuvant is a Toll-like Receptor agonist.

Assignees

• Univ California
• Molecular Express Inc

Inventors

• Fujii Gary
• Szoka Francis C
• Watson Douglas S

Classifications

• C12N2740/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C07J9/00

  Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane · CPC title

• A61K2039/6018

  Lipids, e.g. in lipopeptides · CPC title

• A61K2039/55572

  Lipopolysaccharides; Lipid A; Monophosphoryl lipid A · CPC title

• A61K47/6913 Primary

  the liposome being modified on its surface by an antibody · CPC title